Drug Trial Radar · NCT05347485
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
May 13, 2022
Primary completion
Nov 30, 2023
Study completion Dec 15, 2023
Sponsor
- Lead sponsor
- Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
Conditions
- Multiple Myeloma
Interventions
Cilta-celDrug
Cilta-cel will be administered as an IV infusion.
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)Drug
Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: From Day 1 (post infusion) up to 18.6 months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of California San Francisco
San Francisco, California
Stanford University Medical Center
Stanford, California
Colorado Blood Cancer Institute
Denver, Colorado
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Kansas University Medical Center
Westwood, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Washington University School Of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Mount Sinai Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Medical College Of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.